Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338182 · ClinicalTrials.gov registry record · Phase 1
AZD1152 in Patients With Advanced Solid Malignancies
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT00338182 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 43 participants.
The verdict
NCT00338182, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients with advanced solid malignancies.
Interventions
- DRUG AZD1152 part A
- DRUG AZD1152 part B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2006-05-23 |
| Est. Completion | 2017-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338182
The ClinicalTrials.gov registry entry for NCT00338182 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD1152 part A is the first listed.
NCT00338182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00338182 about?
NCT00338182 is a clinical study titled "AZD1152 in Patients With Advanced Solid Malignancies". The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients with advanced solid malignancies.
What is the current status of trial NCT00338182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2006-05-23. Estimated completion is 2017-03-01.
What interventions are being tested in trial NCT00338182?
The interventions under investigation include: AZD1152 part A (DRUG), AZD1152 part B (DRUG).
Who is sponsoring clinical trial NCT00338182?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.